{
    "clinical_study": {
        "@rank": "158142", 
        "acronym": "FANCY", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "drug: Fulvestrant treatment :  Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.\nThe treatment will continue until disease progression or  intolerable adverse event"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, single arm phase II study to evaluate the efficacy and safety of\n      fulvestrant as a maintenance hormone therapy after first-line chemotherapy for\n      postmenopausal HR positive advanced breast cancer."
        }, 
        "brief_title": "Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, single arm phase II study to evaluate the efficacy and safety of\n      fulvestrant as a maintenance hormone therapy after first-line chemotherapy for\n      postmenopausal HR positive advanced breast cancer.\n\n      Approximately 58 women who have stable disease or responded to first line chemotherapy with\n      at least 4 and less than 8 weeks of treatment for metastatic breast cancer will be enrolled\n      to this study and receive fulvestrant 500mg as a maintenance therapy. The treatment will\n      continue until the objective disease progression or intolerable AE.\n\n      Efficacy will be determined based on tumor assessments performed by each investigator\n      according to RECIST (Response Evaluation Criteria in Solid Tumors ) 1.1. Safety will be\n      monitored based on the frequency and severity of adverse events (AEs), as assessed by Common\n      Terminology Criteria (CTC) grade version 4.0.\n\n      Tumor assessments will be assessed by computed tomography (CT) or magnetic resonance imaging\n      (MRI) every 12 weeks for all patients until documented evidence of objective disease\n      progression.\n\n      Reporting of SAEs (serious adverse events) to regulatory authorities will be done by the\n      investigator in accordance with local regulations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Provision of informed consent Histologically proven HR positive  breast cancer\n\n        Postmenopausal woman, defined as a woman fulfilling any 1 of the following criteria (based\n        on the NCCN definition of menopause [National Comprehensive Cancer Network 2008]):\n\n        Prior bilateral oophorectomy Age \u226560 years Age <60 years and amenorrheic for 12 or more\n        months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and\n        follicle stimulating hormone and oestradiol in the postmenopausal range.\n\n        Patients have completed first-line chemotherapy for metastatic breast cancer The\n        first-line chemotherapy must be given to patients with visceral disease or progressive\n        disease requiring a fast response Responded(CR or PR) or stabilized(SD>=24 weeks) to\n        first-line chemotherapy for metastatic breast cancer The duration of 1st line chemotherapy\n        for advanced breast cancer had been at least 4 cycles and at most 8 cycles WHO performance\n        status 0, 1 or 2-\n\n        Exclusion Criteria:\n\n          -  Presence of life-threatening metastatic visceral disease, defined as extensive\n             hepatic involvement, or any degree of brain or leptomeningeal involvement (past or\n             present) Prior hormonal treatment for metastatic breast cancer are not allowed More\n             than one line of cytotoxic chemotherapy for metastatic breast cancer Her-2 positive\n             Other malignant tumor (concurrent or previous). Any severe concomitant condition\n             which makes it undesirable for the patient to participate in the trial or which would\n             jeopardise compliance with the study protocol, eg, uncontrolled cardiac disease or\n             uncontrolled diabetes mellitus"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000193", 
            "org_study_id": "ISSFASL0042"
        }, 
        "intervention": {
            "arm_group_label": "1", 
            "description": "Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29\uff0c then every 28 days.\nThe treatment will continue until disease progression or  intolerable AE.", 
            "intervention_name": "fulvestrant", 
            "intervention_type": "Drug", 
            "other_name": "Faslodex"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Fulvestrant"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "email": "xufei@sysucc.org.cn", 
                "last_name": "fei xu, M.D.", 
                "phone": "862087342693"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Maintenance Hormone Therapy With Fulvestrant After First-Line Chemotherapy for Postmenopausal Hormone-receptor-positive (HR) Positive Advanced Breast Cancer: A Multicenter, Prospective Phase II Study", 
        "overall_contact": {
            "email": "xufei@sysucc.org.cn", 
            "last_name": "fei xu, M.D", 
            "phone": "862087342693"
        }, 
        "overall_official": {
            "affiliation": "State Key Laboratory of Oncology in South China,  Sun Yat-sen University Cancer Center", 
            "last_name": "shusen wang, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as the proportion of all treated patients who have a best objective tumour response of CR, PR or SD \u2265 24 weeks", 
            "measure": "Clinical Benefit Rate", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000193"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "wang shusen", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Objective Response Rate(ORR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}